Charles Moore,  —

Charles Moore is a syndicated columnist for several major Canadian print newspapers and is the Science and Research Section editor for Multiple Sclerosis News Today.

Articles by Charles Moore

European Program Aims to Develop Wearable Devices to Monitor and Treat MS

A major new European research program to develop waysĀ of monitoring three mainĀ central nervous system diseases ā€”multiple sclerosis (MS), depressive disorder, and epilepsy ā€” using wearable devices and smartphones was launched on April 26. The RADAR-CNS (Remote assessment of disease and relapse Central Nervous System) project, supported by the Innovative…

FDA Invites Comment on Pending Stem Cell Therapy Regulations

The U.S. Food and Drug Administration (FDA) will hold a one-day public hearingĀ on four recent draft guidelines regarding theĀ regulation of human cells, tissues, or cellular or tissue-based products (HCT/Ps). Critics of the proposed regulations warnĀ that they curtail the medical use of autologous cell therapy and biologics, and their future potential…

New MS Drug To Be Distributed By Global Supply Chain Distributor Durbin

Medical Need Europe, a privately held pharmaceutical company headquartered in Sweden and focused on registration, distribution, marketing and sale of orphan drugs and niche speciality pharmaceuticals for treatment of rare diseases, has appointed London, U.K. based Durbin PLC, a leading global supplier and distributor of pharmaceuticals, to manage…

Could Multiple Sclerosis Sufferers Benefit From Cannabis Chewing Gum?

AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…

Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally

Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. ā€œBiogen remains focused on improving the lives of people living with complex diseases,ā€ says Chief Executive Officer George A. Scangos, Ph.D. ā€œTecfidera, which is now…

Most MS Survey Respondents Favor Legal Marijuana Access For Medical Use

With 26 statesĀ plus the District of Columbia now allowing medical marijuana use, according to a recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey, many people with multiple sclerosis are considering the herb as a therapeutic option. NARCOMS is a research program that allows people with Multiple Sclerosis…